GlobeNewswire

Kinnevik participates in VillageMD’s USD 275 million equity funding led by Walgreens Boots Alliance, Inc.

Share

Kinnevik AB (publ) (“Kinnevik”), today announced that it has invested a further USD 25m in VillageMD, a leading national provider of primary care in the US, as part of a USD 275m equity funding led by existing investor Walgreens Boots Alliance, Inc (“WBA”). Including this funding round, WBA will in total invest USD 1bn into VillageMD over the next three years to finance a deepened partnership with VillageMD. In consideration of the partnership and its impact on the future outlook for VillageMD, Kinnevik intends to value its VillageMD investment, excluding the new USD 25m investment, at SEK2.4bn in the upcoming interim report for the second quarter 2020, up SEK1.4bn – or SEK5.2 per Kinnevik share – from the assessment in Kinnevik’s most recent interim report.

VillageMD will open 500 to 700 full-service primary care Village Medical clinics co-located with Walgreens stores in more than 30 US markets over the next five years, with the intent to build several hundred more clinics and enter up to 20 more US markets over time. The clinics will be staffed by more than 3,600 primary care providers, who will be recruited by VillageMD. These clinics will allow VillageMD to benefit from WBA’s strong footfall and brand, and will provide it with a highly attractive and cost-efficient channel to open new markets, scale its risk-bearing primary care model, and solidify its position as the largest independent primary care practice in the US.

Georgi Ganev, CEO of Kinnevik commented: “We invested in VillageMD last year because we believe in the power of value-based care, the differentiation of VillageMD’s technology-enabled care delivery and its mission driven, entrepreneurial culture. This transformative partnership with WBA validates our hypothesis and paves the way for the creation of a truly innovative model at scale combining the best of VillageMD’s care delivery with WBA’s pharmacy capabilities. This not only supports greater health outcomes and improved medication adherence, but also the reduction of the cost of care for both patients and payers.”

To finance the deepened partnership, WBA will invest a total of USD 1bn in equity and convertible debt, including USD 250m of the initial equity funding, into VillageMD over the next three years. Kinnevik will own 10 percent of VillageMD after the initial USD 275m equity funding.

Kinnevik will release its financial results for the second quarter 2020 on 13 July. In consideration of the partnership and its impact on the future outlook for VillageMD, Kinnevik intends to value its VillageMD investment excluding the new USD 25m investment at SEK 2.4bn in this upcoming interim report, up SEK 1.4bn – or SEK 5.2 per Kinnevik share – from the assessment in Kinnevik’s most recent interim report.

Kinnevik led VillageMD’s most recent funding in 2019 with a USD 75m investment. Since then, VillageMD has accelerated the number of its primary care providers, managed lives and medical spend under management. VillageMD has continued to invest in its growth, entering new markets, enhancing its proprietary healthcare operating system, docOS, scaling its virtual care offering and opening new, state-of-the-art Village Medical clinics in Houston, Texas.

About VillageMD

VillageMD, through its subsidiary, Village Medical, is a leading, national provider of value-based primary care services. VillageMD partners with physicians to provide the tools, technology, operations, staffing support and industry relationships to deliver high-quality clinical care and better patient outcomes, while reducing the total cost of care. The Village Medical brand provides primary care for patients at traditional free-standing clinics, Village Medical at Walgreens clinics, at home and via virtual visits. VillageMD and Village Medical have grown to include more than 2,800 physicians across nine markets, are responsible for approximately 600,000 lives and manage USD 4 billion in total medical spend in value-based contracts. To learn more, please visit www.villageMD.com.

This information is information that Kinnevik AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 14.15 CET on 8 July 2020.

For further information, visit www.kinnevik.com or contact:

Torun Litzén, Director Investor Relations
Phone +46 (0)70 762 00 50
Email press@kinnevik.com

Kinnevik is an industry focused investment company with an entrepreneurial spirit. Our purpose is to make people’s lives better by providing more and better choice. In partnership with talented founders and management teams we build challenger businesses that use disruptive technology to address material, everyday consumer needs. As active owners, we believe in delivering both shareholder and social value by building long-term sustainable businesses that contribute positively to society. We invest in Europe, with a focus on the Nordics, the US, and selectively in other markets. Kinnevik was founded in 1936 by the Stenbeck, Klingspor and von Horn families. Kinnevik’s shares are listed on Nasdaq Stockholm’s list for large cap companies under the ticker codes KINV A and KINV B.

Attachment

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Saniona announces outcome of warrant exercise23.9.2020 19:00:00 CESTPress release

PRESS RELEASE September 23, 2020 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, announced today the outcome in the exercise of warrants of series TO 2, that was issued in connection with Saniona’s rights issue and directed issue in the first quarter of 2020. During the period September 7 – 21, 2020, holders of warrants of series TO 2 had the right to subscribe for new shares, by exercise of warrants. In total, 1,329,141 warrants of series TO 2 were exercised, corresponding to a subscription rate of approx. 90 percent. Saniona will thereby receive proceeds of approx. SEK 33.2 million (USD 3.6 million), before issue costs, which amount to approx. SEK 0.4 million. Number of shares and share capital Saniona will receive proceeds of approx. SEK 33.2 million, before issue costs. Issue costs amount to approx. SEK 0.4 million. When the new shares have been registered with the Swedish Companies Registration Office (“Bolagsverket”), the total number o

Saniona meddelar utfall i optionsinlösen23.9.2020 19:00:00 CESTPressemelding

PRESSMEDDELANDE 23 september 2020 Saniona (OMX: SANION), ett biofarmaceutiskt företag med klinisk utveckling fokuserad på sällsynta sjukdomar, meddelade idag utfallet i inlösen av teckningsoptioner av serie TO 2, vilka emitterades i samband med Sanionas företrädesemission och riktade emission under det första kvartalet 2020. Under perioden 7 – 21 september 2020 har innehavare av teckningsoptioner av serie TO 2 kunnat teckna aktier med stöd av teckningsoptioner. Totalt nyttjades 1 329 141 teckningsoptioner av serie TO 2, vilket motsvarar en nyttjandegrad om cirka 90 procent. Saniona tillförs därmed cirka 33,2 MSEK (3,6 MUSD) före emissionskostnader, vilka beräknas uppgå till cirka 0,4 MSEK. Antal aktier och aktiekapital Saniona tillförs cirka 33,2 MSEK före emissionskostnader. Emissionskostnaderna beräknas uppgå till cirka 0,4 MSEK. När de nya aktierna har registrerats hos Bolagsverket kommer antalet aktier i Saniona uppgå till 62 372 831 stycken och aktiekapitalet uppgå till 3 118 641,

SEK TENDER OPERATION ANNOUNCEMENT FOR ONWARD LENDING23.9.2020 16:20:00 CESTPress release

SEK TENDER OPERATION ANNOUNCEMENT FOR ONWARD LENDING 2020-09-25 Transaction type:SEK CreditTender date:2020-09-25Time for submission of bids:10.30-11.00 (CEST)Payment date:2020-09-29Final repayment date2024-09-30Offered volume:50 billion SEKMinimum bid amount:10 million SEKMaximum bid amount:12.5 billion SEKMaximum number of bids from each participant: 1Interest rate:0.00 %Additional interest rate:0.10 per cent ALL APPROVED COUNTERPARTIES ARE INVITED TO SUBMIT VOLUME BIDS TO THE RIKSBANK (46-8-6966970) BY 11.00 ON SEPTEMBER 25 2020, AT THE LATEST. CONFIRMATION ON E-MAIL: eol@riksbank.se Result of the auction will be published at 11.30 (CEST) on Tender date. Complete terms and conditions can be retrieved at http://www.riksbank.se

Cypress Development to Collaborate on Lithium Research Projects23.9.2020 14:00:10 CESTPress release

VANCOUVER, British Columbia, Sept. 23, 2020 (GLOBE NEWSWIRE) -- Cypress Development Corp. (TSX-V:CYP) (OTCQB:CYDVF) (Frankfurt:C1Z1) (“Cypress” or “the Company”), developer of a world class lithium claystone deposit in Nevada, announced today, the Company, as an industrial partner with several high tech research entities, has been encouraged along with its partners in full project proposal submissions to the Department of Energy (DOE), Office of Energy Efficiency and Renewable Energy (EERE). This has culminated in the recent formal submittal of two lithium project proposals for research to be conducted over the next three years. The first project is in collaboration with the University of Utah, Colorado School of Mines, and Cornell University, and is titled "Highly Selective Resource Independent Lithium Extraction Processes." This technology will demonstrate the use of Next Generation Lithium Ion Sieve Technology (NGLIST) as an innovative and low-impact processing method for recovering

Nordic American Tankers Ltd (NYSE: NAT) – NAT orders two -2- Suezmax newbuildings in South Korea23.9.2020 11:54:47 CESTPress release

September 23, 2020 Dear Shareholders and Investors, We wish to announce that NAT has entered into two -2- suezmax newbuilding contracts in South Korea, increasing our fleet of suezmaxes to 25 units. The combination of specifications, quality of yard, price, payment terms and deliveries make this an attractive investment for NAT and is consistent with our strategy to expand and renew our fleet. The scheduled deliveries of the ships are in the first half of 2022. Through the years we have enjoyed an excellent relationship with the shipbuilding sector in South Korea, and we are happy to conclude further suezmax newbuilding contracts with Samsung Heavy Industries Ltd. NAT will consider various financing alternatives prior to deliveries. The payment terms of the newbuildings are 10/10/10/10 with 60% of the building price on deliveries. The two first instalments of the vessels have already been funded. The main focus of NAT is always to pay quarterly dividends, which we have done every singl